-
2024-511650-50-00
5
2025-01-17
METASTATIC CASTRATION RESISTANT PROSTATE CANCER
-
2024-513540-29-00
5
2024-11-07
Breast Cancer
-
2023-505972-32-00
5
2024-02-26
locally advanced anal squamous cell carcinoma
-
2024-512573-27-01
4
2023-12-11
Muscle-invasive bladder cancer (MIBC)
-
2022-501024-20-00
5
2023-07-25
ER+/HER2- Early Breast Cancer
-
2024-512224-11-00
4
2023-03-24
Histologically confirmed frail Limited Disease Small Cell Lung Cancer
-
2023-510061-10-00
3
2023-01-09
Clear cell renal cell carcinoma (ccRCC, first-, second- and third-line
-
2024-514644-93-00
5
2022-12-09
Metastatic renal cell carcinoma (mRCC) with a good or only one adverse
-
2024-514480-26-00
4
2022-10-12
Post-menopausal women with localized luminal A breast cancer and consi
-
2023-504195-14-00
5
2022-08-31
PD-L1-negative metastatic triple-negative breast cancer or PD-L1-posit
-
2023-504996-26-00
5
2022-07-21
Metastatic Castration Resistant Prostate Cancer (mCRPC)
-
2023-503826-37-00
5
2022-02-11
Unresectable locally-advanced or metastatic HER2+ breast cancer
-
2024-515604-39-00
5
2022-01-28
Metastatic castration-resistant prostate cancer (mCRPC)
-
2023-509133-39-00
5
2021-11-29
Hormone receptor positive, HER2-negative advanced breast cancer
-
2022-502705-15-00
5
2021-03-08
High-risk muscle-invasive bladder cancer
-
2023-510390-33-00
5
2020-10-23
HER2-negative breast cancer patients with high relapse risk after
stan
-
2024-518506-41-00
9
2020-10-05
metastatic castrate resistant prostate cancer
-
2024-516481-11-00
5
2020-09-22
Metastatic Castration-Resistant Prostate Cancer
-
2023-505812-39-00
5
2020-08-28
HR+/HER2-Negative Locally Advanced or Metastatic Breast cancer with PI
-
2023-506782-56-00
5
2020-03-10
RET-Mutant Medullary Thyroid Cancer
-
2023-505223-31-00
4
2019-06-14
Localized ER+ breast cancer
-
2023-509671-17-00
5
2017-07-12
Breast Cancer
-
2024-510704-37-00
5
2017-03-22
ER+/HER2- metastatic breast cancer
-
2024-511096-15-00
5
2014-08-01
Breast Cancer